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Abstract
Background: Traumatic brain injury (TBI) initiates a neuroinflammatory cascade that contributes to neuronal damage and
behavioral impairment. This study was undertaken to investigate the effects of wogonin, a flavonoid with potent anti-
inflammatory properties, on functional and histological outcomes, brain edema, and toll-like receptor 4 (TLR4)- and nuclear
factor kappa B (NF-kB)-related signaling pathways in mice following TBI.
Methodology/Principal Findings: Mice subjected to controlled cortical impact injury were injected with wogonin (20, 40, or
50 mg?kg
21) or vehicle 10 min after injury. Behavioral studies, histology analysis, and measurement of blood-brain barrier
(BBB) permeability and brain water content were carried out to assess the effects of wogonin. Levels of TLR4/NF-kB-related
inflammatory mediators were also examined. Treatment with 40 mg?kg
21 wogonin significantly improved functional
recovery and reduced contusion volumes up to post-injury day 28. Wogonin also significantly reduced neuronal death, BBB
permeability, and brain edema beginning at day 1. These changes were associated with a marked reduction in leukocyte
infiltration, microglial activation, TLR4 expression, NF-kB translocation to nucleus and its DNA binding activity, matrix
metalloproteinase-9 activity, and expression of inflammatory mediators, including interleukin-1b, interleukin-6, macrophage
inflammatory protein-2, and cyclooxygenase-2.
Conclusions/Significance: Our results show that post-injury wogonin treatment improved long-term functional and
histological outcomes, reduced brain edema, and attenuated the TLR4/NF-kB-mediated inflammatory response in mouse
TBI. The neuroprotective effects of wogonin may be related to modulation of the TLR4/NF-kB signaling pathway.
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Introduction
Traumatic brain injury (TBI) induces a complex series of
inflammatory responses that contribute to neuronal damage and
behavioral impairment [1]. Toll-like receptors (TLRs) are a family
of signal transduction molecules known to activate the innate
immune response following systemic bacterial infection and
cerebral injury [2]. Among the TLRs, TLR4 has been shown to
play an important role in initiating the inflammatory response in
the damaged brain. Several animal studies have shown that both
TLR4 mRNA and protein are upregulated following TBI [3–5].
TLR4-mediated signaling pathways mainly stimulate the activa-
tion of nuclear factor kappa B (NF-kB). This important nuclear
transcription factor regulates many pro-inflammatory genes, e.g.,
cytokines, chemokines, cyclooxygenase-2 (COX-2), and matrix
metalloproteinase-9 (MMP-9), mediators involved in the patho-
genesis of TBI [6]. TLR4-deficient mice exhibited reduced infarct
size and improved neurological recovery as well as less
inflammatory response following cerebral ischemia [7,8]. Further-
more, neurons from TLR4 mutant mice were protected against
energy deprivation-induced cell death, which was associated with
decreased activation of pro-apoptotic c-Jun N-terminal kinase
signaling [7]. These studies suggest that pharmacological inhibi-
tion of TLR4/NF-kB signaling may be a useful strategy for
protection of the injured brain.
Wogonin, 5,7-dihydroxy-8-methoxyflavone, is one of the major
flavonoids found in the root of the Chinese herb Scutellaria
baicalensis Georgi (also called Huang-Qin), which is widely used in
treating allergic and inflammatory diseases [9]. Wogonin has been
shown to exert potent anti-inflammatory effects in both in vitro and
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suppresses lipopolysaccharide (LPS)-induced production of nitric
oxide (NO), prostaglandin E2, and pro-inflammatory cytokines in
immune cells such as macrophages and microglial cells [10–12]
and reduces migration in microglial cells via inhibition of NF-kB
activity [13]. In addition, treatment with wogonin was found to
alleviate inflammatory responses caused by skin inflammation and
carrageenan-induced hindpaw edema in animal studies [14,15].
Increasing evidence suggests that wogonin may have neuropro-
tective effects in the injured brain. Wogonin attenuated the death
of hippocampal neurons and inhibited microglia activation in
global ischemia and excitotoxic injury models [11]. Furthermore,
wogonin also reduced early ischemic brain injury and improved
acute behavioral dysfunctions caused by focal cerebral ischemia
[16,17]. In addition, wogonin attenuated excitotoxic and oxidative
stress-induced neuronal damage in primary cultured rat cortical
cells [18] and reduced neuronal damage caused by exposure to
oxygen and glucose deprivation in cultured rat hippocampal slices
[19]. Despite evidence indicating the benefits of wogonin
treatment to early neurological recovery in stroke models, there
is a lack of data describing the long-term effects of wogonin on
functional recovery or cell survival in the injured brain. In
particular, the neuroprotective effects of wogonin on TBI have not
been established.
The aim of the present study was to investigate the protective
effects of wogonin on neuronal damage, brain edema, and
functional impairment after TBI. We further examined whether
wogonin could attenuate TBI-induced activation of the TLR4/
NF-kB signaling pathway in the pericontusional area.
Results
Metabolic characteristics
There were no significant differences in the levels of plasma
blood urea nitrogen (BUN), creatinine (CRE), alanine amino-
transferase (ALT), or aspartate aminotransferase (AST) between
the vehicle-treated and 40 mg?kg
21 wogonin-treated injured mice
(Table 1). The mice in both groups lost a small proportion of body
weight (,6%) during the initial 2 days after CCI, but regained
baseline weight within 7 days. No significant difference in body
weight was detected between groups treated with wogonin or
vehicle (P=0.8261, data not shown).
Post-injury wogonin administration improves
neurobehavioral recovery following TBI Rotarod test
We first conducted several sets of behavioral experiments to
verify whether post-injury wogonin treatment could improve
recovery from neurologic deficits. TBI induced persistent motor
function impairment with a significant decrease in rotarod running
time from 1 to 28 days in the vehicle-treated group (Fig. 1A).
Treatment with 20 mg?kg
21 wogonin did not significantly alter
rotarod performance compared with the vehicle-treated group.
Nevertheless, performance on the rotarod test was significantly
better for 40 mg?kg
21 wogonin-treated mice than for vehicle-
treated mice on test days 1–28 after injury (all P,0.05). In
addition, mice treated with 50 mg?kg
21 wogonin had better
performance in the rotarod test at days 1, 7, 14, 21, and 28 than
vehicle-treated mice (all P,0.05). There was no significant
difference between 40 mg?kg
21- and 50 mg?kg
21-treated-groups
at all tested time points.
Modified neurological severity score
Injury in the left hemispheric cortex resulted in neurological
deficits as measured by modified neurological severity score
(mNSS) (Fig. 1B). There was no significant difference between
20 mg?kg
21 wogonin-treated and vehicle-treated groups at all
tested time points. The mNSS scores were significantly lower in
both the 40 mg?kg
21 and 50 mg?kg
21 wogonin-treated group
than the corresponding vehicle-treated group on test days 1–28
after injury (all P,0.05). There was no significant difference
between the 40 mg?kg
21- and 50 mg?kg
21-treated groups at all
tested time points.
Beam walk test
Marked impairment in beam walk performance including
decrease in hindlimb motor scores and increase in beam walk
latency (traversing latency) was observed on the first day after
surgery, regardless of treatment (Fig. 1C). There was no
significant difference between the 20 mg?kg
21 wogonin-treated
and vehicle-treated groups at all tested time points. The decrease
in hindlimb motor scores was significantly different between the
40 mg?kg
21 wogonin-treated group and vehicle-treated group on
test days 1–28 after injury (all P,0.05) and between the
50 mg?kg
21-dose group and vehicle group on days 4, 7, 14, 21,
and 28 (all P,0.05). However, differences in hindlimb motor
scores between the 40 mg?kg
21 and 50 mg?kg
21 groups were not
significant on any testing day (all P.0.05). Likewise, beam walk
latencies were significantly shorter for both the 40 mg?kg
21 and
50 mg?kg
21 groups than for the vehicle group on days 1, 4, and 7
(all P,0.05), though no significant differences between the 2
wogonin-treated groups were found (Fig. 1C). Furthermore,
though beam walk latencies on days 14, 21, and 28 were shorter
for both the 40 mg?kg
21 and 50 mg?kg
21 groups than for the
vehicle group, these differences did not reach statistical
significance.
Post-injury wogonin administration reduces cortical
contusion volume, blood-brain barrier permeability, and
brain edema
Since 40 mg?kg
21 wogonin treatment significantly improved
neurological outcomes, we further investigated whether this
treatment paradigm reduced neuronal damage, brain edema,
and post-traumatic inflammation. Brain sections taken from
controlled cortical impact (CCI) mice revealed a loss of cortical
tissue in the ipsilateral parietal cortex as reflected by gross
reductions in cresyl violet staining intensity (Fig. 2A). Quantifica-
tion of cortical volume showed that at day 1 after CCI, there was a
22.9% reduction in contusion volume in 40 mg?kg
21 wogonin-
treated mice compared with vehicle-treated controls. Contusion
volume in the wogonin group was 14.161.0 mm
3 versus
18.361.4 mm
3 in the vehicle group (P,0.05; Fig. 2A). Long-
Table 1. Metabolic characteristics of the sham control, mice
treated with DMSO and 40 mg?kg
21 wogonin.
Day 1 Day 28
Sham Vehicle Wogonin Vehicle Wogonin
BUN (mg/dL) 20.0061.30 21.2061.50 19.3061.60 20.5061.20 18.5061.80
CRE (mg/dL) 0.2760.07 0.2060.10 0.2760.07 0.2760.09 0.3360.07
ALT (mg/dL) 28.30610.2027.2062.60 25.8062.10 22.9062.30 23.7062.10
AST (mg/dL) 46.7068.50 46.0069.80 35.7066.30 43.0068.20 45.7069.20
Values are expressed as means 6 SEM. n=7/groups. BUN: blood urea nitrogen;
CRE: creatinine; AST: aspartate aminotransferase; ALT: alanine aminotransferase.
doi:10.1371/journal.pone.0030294.t001
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cortical contusion volume in the vehicle-treated TBI group was
measured to be 12.060.9 mm
3 (Fig. 2A). Treatment with wogonin
resulted in reduction of lesion size by 24.2% to 9.160.8 mm
3,
which was significantly smaller than the vehicle-treated group
(P,0.05; Fig. 2A).
Disruption of the blood-brain barrier (BBB) and brain edema
can cause brain swelling and increased intracranial pressure
following TBI, leading to secondary injury and cell death [20].
To assess whether the reduction in neurological deficits and brain
injury after wogonin treatment correlated with reduced BBB
disruption and brain edema, we next examined hemispheric
enlargement and brain water content 1 day post-TBI. BBB
permeability was determined by Evans blue (EB) dye extravasa-
tion. There was a marked increase in EB content in the ipsilateral
hemisphere of the vehicle-treated TBI group as compared with
the sham control (8.360.5 mg?g
21 versus 1.660.2 mg?g
21,
P,0.001; Fig. 2B). TBI-induced increases in EB dye extravasa-
tion in the ipsilateral hemisphere were significantly reduced by
wogonin treatment at day 1 post-TBI (8.360.5 mg?g
21 versus
5.860.7 mg?g
21, P,0.01). Because BBB breakdown may lead to
accumulation of circulating fluid and contribute to brain edema
[21], we further assessed whether wogonin treatment could
reduce brain edema at day 1, when brain edema reached the
Figure 1. Effects of 3 different doses of wogonin on functional outcomes in contusion-injured mice. (A) Compared to the vehicle
treatment, 20 mg?kg
21 wogonin treatment did not significantly alter rotarod performance. On days 1–28, 40 mg?kg
21 wogonin-treated mice
performed significantly better than the vehicle-treated mice. On days 1, 7, 14, 21, and 28, the 50 mg?kg
21 wogonin-treated mice had better rotarod
performance than the vehicle-treated mice. No significant differences were observed between the 40 mg?kg
21 and 50 mg?kg
21 wogonin treatment
groups at any time point. (B) No difference in modified Neurological Severity Score (mNSS) was detected between the 20 mg?kg
21 wogonin and
vehicle treatment groups. On days 1–28, the mNSSs were significantly lower in the 40 mg?kg
21 and 50 mg?kg
21 dose groups than in the vehicle-
treated group. No significant differences were observed between the 40 mg?kg
21 and 50 mg?kg
21 treatment groups. (C) During the beam walk test,
no significant differences were observed between the 20 mg?kg
21 wogonin-treated and vehicle-treated groups. Significant differences were
observed in the hindlimb motor scores between the 40 mg?kg
21 wogonin-treated and vehicle-treated groups on post-injury test days 1–28 and
between the 50 mg?kg
21 dose group and vehicle group on days 4, 7, 14, and 21. Differences in hindlimb motor scores between the 40 mg?kg
21 and
50 mg?kg
21 groups were not significant. Beam walk latencies were significantly shorter for both the 40 mg?kg
21 and 50 mg?kg
21 groups than for
the vehicle group, on days 1, 7, 14, and 28; however, no significant difference was observed between the 2 wogonin-treated groups. Values are




mice versus the 40 mg?kg
21 wogonin-treated mice.
#P,0.05: 20 mg?kg
21 wogonin-treated mice versus the 50 mg?kg
21 wogonin-treated mice
(n=8 mice/group at each time point).
doi:10.1371/journal.pone.0030294.g001
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indicator of brain edema, was significantly increased in the
ipsilateral hemisphere by day 1 in vehicle-treated TBI mice
compared with that of sham controls (82.860.6% versus
77.060.4%, P,0.001; Fig. 2C). Treatment with wogonin caused
a reduction in the percent water content within the ipsilateral
hemisphere cortex compared with the vehicle-treated group
(80.960.5% versus 82.860.6%, P,0.05; Fig. 2C). Similarly,
hemispheric enlargement was significantly smaller in wogonin-
treated mice (10.961.1%) than in the vehicle-treated mice
(14.561.1%, P,0.05; Fig. 2D).
We next sought to determine the effects of wogonin on 2 major
proteins involved in tight junctions of the BBB, claudin-5 and
zonula occludens (ZO)-1. TBI caused a significant decrease in
both claudin-5 and ZO-1 expression at day 1 after injury (Figs. 2E
& F). However, this apparent loss of claudin-5 and ZO-1 was
reversed after wogonin treatment. Protein expression of claudin-5
and ZO-1 in the injured cortex of wogonin-treated mice was
increased to 181.6% (P,0.05) and 164.8% (P,0.05) of the vehicle
group, respectively.
Post-injury wogonin administration reduces neuronal
and apoptotic cell death
We used Fluoro-Jade B (FJB) and terminal deoxynucleotidyl
transferase-mediated dUTP-biotin nick end labeling (TUNEL)
staining to examine whether neuronal death was decreased in the
pericontusion region of wogonin-treated mice. Since FJB and
TUNEL reactivity has been shown to peak 1 day after CCI
[22,23], the day 1 time point was chosen. Both FJB-positive cells
with neuronal morphology and TUNEL-positive cells were
evident at day 1 after injury in the cortical contusion margin
(Figs. 3A & B) and striatum in the ipsilateral but not the
contralateral hemisphere. Wogonin-treated mice had significantly
fewer FJB-positive neurons around the injured cortical areas at
day 1 post-injury than observed in the vehicle-treated group
(85.769.0 versus 126.7612.1 cells/field, P,0.05; Fig. 3A).
Furthermore, TUNEL staining showed that the number of
apoptotic cells increased markedly in cerebral tissues surrounding
the injured area in TBI groups at 24 h post-injury. Significantly
fewer TUNEL-positive cells were found around injured cortical
Figure 2. Effects of 40 mg?kg
21 wogonin treatment on cortical contusion volume, brain edema, and BBB permeability. (A)
Representative cresyl violet-stained brain sections of vehicle- and 40 mg?kg
21 wogonin-treated mice 1 day post-TBI showing hypointense regions
immediately below the impact site in the cortex. Scale bar is 1 mm. Quantification showed significantly smaller contusion volumes in wogonin-
treated mice compared with vehicle-treated mice at days 1 and 28 post-TBI. (B) Wogonin-treated mice showed a significant decrease in the
concentration of Evans blue (EB) in the ipsilateral hemisphere compared with vehicle-treated mice at day 1. (C) Brain water content in the ipsilateral
hemisphere of 40 mg?kg
21 wogonin-treated mice was significantly lower than in vehicle-treated mice at day 1. (D) At day 1, hemispheric
enlargement was significantly smaller in mice treated with 40 mg?kg
21 wogonin than in vehicle-treated mice. (E, F) Treatment with 40 mg?kg
21
wogonin also reversed TBI-mediated reduced expression of claudin-5 and zonula occludens 1 in traumatic cortical areas of the ipsilateral hemisphere
at day 1 following TBI, as measured by western blot. Values are presented as mean 6 SEM; **P,0.01, ***P,0.001 versus vehicle-treated injured mice.
{P,0.05,
{{P,0.01 for the 40 mg?kg
21 wogonin-treated mice versus vehicle-treated mice. (n=8 mice/group for cresyl violet staining and
hemispheric enlargement, n=7 mice/group for brain EB, brain water content, and western blot).
doi:10.1371/journal.pone.0030294.g002
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treated controls (70.466.3%, P,0.05; Fig. 3B).
Post-injury wogonin administration reduces neutrophil
infiltration and microglial activation
The above results suggest that wogonin may improve functional
recovery and reduce neuronal damage following TBI. We further
explored whether wogonin treatment directly influenced post-
injury early inflammatory events. Since neutrophil infiltration and
microglial activation may contribute to TBI-induced tissue injury,
we examined whether wogonin treatment had any effects on
infiltrated neutrophils and activated microglia/macrophages. We
found that TBI produced a robust infiltration of neutrophils in the
injured cortex, primarily in the contusion core and margin, in
vehicle-treated mice. Furthermore, wogonin-treated mice had
significantly fewer neutrophils in the pericontusion area than did
vehicle-treated mice (110.069.9 versus 177.4620.0 cells/field,
P,0.05; Figs. 4A & B). With regard to the microglial response,
there was a significant increase in ionized calcium binding adaptor
molecule 1 (Iba1)-positive microglia within the injured cortex in
the vehicle-treated group. This increase was attenuated by
wogonin treatment as well (86.067.8 versus 126.3612.6 cells/
field, P,0.01; Fig. 4A & B).
Post-injury wogonin administration reduces IL-1b, IL-6,
MIP-2, and COX-2 expression, but has no effect on MCP-1
expression after TBI
We next assessed the effects of wogonin treatment on the
expression of inflammatory mediators. Since our previous studies
showed that the mRNA and protein expression of most cytokines
peaked at 6 and 24 h after TBI, respectively [24], we chose to
evaluate the wogonin effect on mRNA and protein expression of
various inflammatory mediators at 6 h and 1 day post-injury.
Protein expression of interleukin (IL-1b), IL-6, macrophage
inflammatory protein (MIP)-2 and monocyte chemoattractant
protein (MCP)-1 was detected using enzyme-linked immunosor-
bent assay (ELISA) whereas that of COX-2 was detected using
western blot. mRNA expression of all the inflammatory mediators
was detected by real-time quantitative reverse transcription
polymerase chain reaction (RT-PCR) analysis. Basal levels of IL-
Figure 3. Effects of 40 mg?kg
21 wogonin treatment on neuronal degeneration and apoptotic cell death. (A) Brain atlas of coronal
sections of a core contusional region at 0.74 mm from the bregma. Quantification analysis indicated that wogonin-treated mice had significantly
fewer degenerating neurons than vehicle-treated mice in the cortical contusion margin at day 1 post-TBI. The total number of Fluoro-Jade B (FJB)-
positive cells is expressed as the mean number per field of view (1.3 mm
2). The scale bar is 50 mm. (B) Representative terminal deoxynucleotidyl
transferase-mediated dUTP-biotin nick end labeling (TUNEL) staining (green)- and DAPI (blue)-stained brain sections of a sham-injured control, a
wogonin-treated mouse, and a vehicle-treated mouse at day 1 post-TBI. Quantification showed that wogonin-treated mice had significantly fewer
TUNEL-positive cells than the vehicle-treated mice in the cortical contusion margin at day 1 post-TBI. The percentage of TUNEL-positive cells is
expressed as the number of TUNEL-stained nuclei/the total number of DAPI-stained nuclei. Sections were stained with DAPI (blue) to show all nuclei.
The scale bar is 50 mm. Values are presented as means 6 SEM; *P,0.05 versus vehicle-treated injured mice (n=7 mice/group).
doi:10.1371/journal.pone.0030294.g003
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brains. However, TBI induced a significant increase in IL-1b, IL-
6, MIP-2, MCP-1, and COX-2 protein expression in the injured
cortex of both vehicle-treated and wogonin-treated mice com-
pared with the sham control at day 1 post-injury (Figs. 5A–D &
6A). Injured cortices from wogonin-treated mice exhibited
significantly reduced IL-1b, IL-6, MIP-2, and COX-2 protein
levels compared with the vehicle group (IL-1b: 49.1612.7 versus
84.969.4 pg?mg
21 protein, P,0.05, Fig. 5A; IL-6: 86.568.1
versus 130.7611.6 pg?mg
21 protein, P,0.01, Fig. 5B; MIP-2:
156.5617.4 versus 221.7611.3 pg?mg
21 protein, P,0.01,
Fig. 5C; COX-2: 70.6% of the vehicle group, P,0.05, Fig. 6A).
Though MCP-1 protein levels appeared to follow the same trend,
the changes were not statistically significant (Fig. 5D). Similarly,
mRNA levels of IL-1b, IL-6, MIP-2, MCP-1 and COX-2
increased significantly in the injured cortices of vehicle-treated
mice at 6 h post-injury compared with sham controls (P,0.05 for
all values; Figs. 5E–H & 6A). The increase in IL-1b, IL-6, MIP-2,
and COX-2 mRNA levels was significantly attenuated by wogonin
treatment. IL-1b, IL-6, MIP-2, and COX-2 mRNA levels in the
wogonin-treated injured cortex were 56.0% (P,0.01; Fig. 5E),
73.5% (P,0.05; Fig. 5F), 54.2% (P,0.01; Fig. 5G), and 47.7%
(P,0.01; Fig. 6B) of the vehicle group at 6 h, respectively. In
contrast, no significant differences were found for MCP-1 mRNA
(Fig. 5H).
Post-injury wogonin administration reduces MMP-9
enzymatic activity after TBI
MMP-9 activity was significantly increased in both vehicle-
treated and wogonin-treated injured brains at day 1 post-TBI
(Fig. 6C). MMP-9 activity was significantly decreased in wogonin-
treated mice compared with vehicle-treated mice (P,0.05).
Post-injury wogonin administration reduces NF-kB
binding activity after TBI
NF-kB is a major transcription factor that regulates the
expression of several genes involved in the inflammatory response.
To investigate the time-course expression of NF-kB activation,
western blot analyses were performed with nuclear extracts. Basal
nuclear NF-kB p65 levels were low in the cortex of the sham-
injured animals. Activation of NF-kB, as indicated by the nuclear
translocation of p65 was observed at 1, 3, 6 and 24 h after injury,
with the peak level being observed at 3 h (P,0.05 for all values)
Figure 4. Effects of 40 mg?kg
21 wogonin treatment on neutrophil infiltration and microglial activation. (A) Representative
myeloperoxidase (MPO)- and anti-ionized calcium binding adaptor molecule 1 (Iba1)-stained brain sections from a sham-injured control, a wogonin-
treated, and a vehicle-treated mouse at day 1 post-TBI. (B) Cell count analysis indicated that wogonin-treated mice had significantly fewer infiltrating
neutrophils and activated microglia/macrophages than vehicle-treated mice in the cortical contusion margin at day 1 post-TBI. The total number of
MPO- and Iba1-positive cells is expressed as the mean number per field of view (1.3 mm
2). The scale bar is 100 mm. Values are presented as means 6
SEM; *P,0.05, **P,0.01 versus vehicle-treated TBI mice (n=7 mice/group).
doi:10.1371/journal.pone.0030294.g004
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induced increased nuclear levels of NF-kB to 55.3% (P,0.05) of
vehicle-treated brains at day 1 post-TBI (Fig. 6E). We further used
electrophoretic mobility shift assays (EMSAs) to examine whether
wogonin affected the DNA binding activity of NF-kB. NF-kB was
present at low levels in sham control brains. Compared with the
sham group, NF-kB binding activity was significantly increased in
the vehicle-treated TBI group at day 1 post-TBI (Fig. 6F).
Wogonin treatment significantly reduced NF-kB binding activity.
NF-kB binding activity in the injured brains of wogonin-treated
mice was 61.3% (P,0.05) of vehicle-treated control brains at day
1.
Post-injury wogonin administration reduces TLR-4
protein expression after TBI
Since activation of TLR4 stimulates the activation of NF-kB, we
next examined the effects of wogonin on TLR4 protein expression.
Basal TLR4 expression was low in sham control brains. The
expression of TLR4 significantly increased starting from 1 h after
injury (P,0.05), and remained high between 3 h to 1 day post-
TBI (P,0.05 for all values) (Fig. 7A). At day 1 post-injury, TLR4
protein expression was significantly increased in the injured cortex
of both vehicle-treated and wogonin-treated mice compared with
sham controls (Fig. 7B). Dual-label immunofluorescence demon-
strated that TLR4 was co-localized in neurons and astrocytes, and
poor co-localization was observed in microglia, in the peri-
contusional area (Fig. 7C). Wogonin treatment significantly
reduced TLR4 levels to 73.0% (P,0.05) of vehicle-treated control
brains (Fig. 7B).
Discussion
This study shows for the first time that wogonin administered
10 min after CCI reduces neuronal damage and cerebral edema
and improves long-term sensory-motor recovery after TBI in mice.
These beneficial effects are associated with a reduction in mRNA
transcripts and protein expression of TLR4/NF-kB pathway-
related mediators. Our results demonstrate that wogonin treat-
ment is effective at attenuating the severity of TBI in mice, both
clinically and neuropathologically.
TBI induces neurological deficits and can result in functional
impairment as well as dependence. In clinical studies, the
functional outcome following a traumatic insult is one of the most
important parameters. We observed that wogonin treatment
caused a significant reduction in both sensory-motor deficits
(assessed by mNSS) and motor dysfunction (assessed by rotarod
and beam walk tests) up to 4 weeks post-injury, indicating that
wogonin was highly effective in providing long-lasting protection
to the traumatized brain. We utilized rotarod and beam walk tests
to measure motor coordination and balance [24,25], and mNSS to
evaluate overall neurological deficits [24]. Notably, we found that
a single dose of wogonin reduced functional deficits caused by
experimental TBI in mice as early as 1 day post-injury and
promoted sustained improvement of motor-sensory functions over
a 4-week post-injury period. The protection afforded by wogonin
was associated with a decrease in neuronal damage and apoptotic
cell death at day 1, and a reduction in contusion volume at both
day 1 and day 28 in the cortical regions involved in motor and
sensory functions. These findings suggest that wogonin effectively
Figure 5. Effects of 40 mg?kg
21 wogonin treatment on protein and mRNA expression of cytokines and chemokines. (A, B, C, D) Bar
graphs of interleukin (IL)-1b, IL-6, macrophage inflammatory protein (MIP)-2, and monocyte chemoattractant protein (MCP)-1 protein concentrations
in the ipsilateral cortices of sham control, vehicle-treated, and 40 mg?kg
21 wogonin-treated mice at day 1 post-injury. Wogonin significantly
attenuated injury-induced increases in IL-1b, IL-6, and MIP-2 protein concentrations, but had no effect on MCP-1 protein concentration compared
with vehicle-treated TBI mice. (E, F, G, H) Bar graphs demonstrating IL-1b, IL-6, MIP-2, and MCP-1 mRNA expression in the ipsilateral cortices of sham
control, vehicle-treated, and 40 mg?kg
21 wogonin-treated mice 6 h post-injury. Wogonin significantly inhibited injury-induced expression of IL-1b, IL-
6, and MIP-2 mRNA in the ipsilateral cortices. There was no significant difference in MCP-1 mRNA transcript levels between the wogonin-treated and
vehicle-treated groups of mice subjected to TBI. Values are presented as means 6 SEM; **P,0.01, ***P,0.001 versus sham control, and
{P,0.05,
{{P,0.01 for wogonin-treated mice versus vehicle-treated TBI mice (n=7 mice/group).
doi:10.1371/journal.pone.0030294.g005
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deficits during the first 24 h, which consequently led to a better
prolonged recovery of neurologic function.
TLR4-mediated NF-kB signaling plays a vital role in the
initiation of cerebral inflammation in several central nervous
system (CNS) diseases, such as inflammatory or autoimmune CNS
diseases, and cerebral ischemic injury [2,26]. The activation of
NF-kB leads to transcription of many pro-inflammatory genes that
encode cytokines, chemokines, and enzymes such as COX-2 and
MMP-9, mediators that are involved in the development of
secondary brain injury following TBI [27,28]. The upregulation of
cytokines and chemokines, e.g., IL-1b, IL-6, and MIP-2, may
activate microglia, initiate the infiltration of inflammatory cells
into the brain, and trigger a series of events ultimately leading to
neuronal death [1,29,30]. In addition, MMP-9 can degrade the
neurovascular matrix, leading to edema and tissue injury [28,31].
Induction of COX-2 up-regulates prostaglandin production,
generates free radical species, and contributes to edema and
neuronal death [32]. Here, we showed that wogonin treatment
could attenuate TBI-induced reduced TLR4/NF-kB signaling
pathway activation in the injured brain. It is possible that wogonin
suppressed microglia activation and neutrophil infiltration and
reduced injury-induced IL-1b, IL-6, MIP-2, MMP-9, and COX-2
expression, thereby ameliorating brain damage. Our results are in
agreement with previous studies demonstrating that suppression of
TLR4/NF-kB signaling by anti-inflammatory agents, including
statins and progesterone, reduced TBI-induced brain damage
[4,5]. There is abundant evidence showing that wogonin
attenuates several inflammatory processes known to be important
during TBI. For example, wogonin has been shown to alleviate
inflammatory processes by decreasing prostaglandin E2 produc-
tion and COX-2 expression in macrophages [10]. Wogonin
Figure 6. Effects of 40 mg?kg
21 wogonin on COX-2 expression, MMP-9 and NF-kB activation. (A) Representative immunoblots and
densitometry analysis showed a significant decrease in COX-2 protein levels in the ipsilateral hemispheres of wogonin-treated injured mice at day 1
compared with vehicle-treated injured mice. (B) Bar graphs showed that wogonin significantly reduced COX-2 mRNA expression in the ipsilateral
hemispheres compared with vehicle-treated injured mice at 6 h post-TBI. (C) Representative zymography and densitometry analysis showed that
MMP-9 activity was significantly decreased in wogonin-treated mice compared with vehicle-treated mice at day 1. (D) Representative immunoblots of
nuclearNF-kB p65 in the ipsilateral hemisphere of untreated injured mice. Densitometric analysis showed increased nuclear p65 levels at 1, 3, 6 and
24 h post-injury, with a peak at around 3 h.
#P,0.05 versus 3 h (n=5 mice/time point). (E) Representative immunoblots and densitometric analysis
showed a significantly greater decrease in nuclear NF-kB p65 levels in the ipsilateral hemispheres of the wogonin-treated injured mice than in the
vehicle-treated injured mice at day 1. (F) Representative gel shift analysis showing NF-kB DNA-binding activity from a sham control mouse (lane 3),
vehicle-treated injured mouse (lane 4), and wogonin-treated injured mouse (lane 5) at day 1. Competition assays for NF-kB DNA-binding activity were
performed with a 50-fold excess of unlabeled competitor NF-kB consensus oligonucleotides (lane 1). For the supershift assay, an antibody targeting
the p65 subunit of NF-kB was incubated with a nuclear protein sample before the binding reaction (lane 2). Quantification analysis showed that
wogonin treatment induced a significantly greater decrease in NF-kB binding activity, expressed in arbitrary densitometric units (ADU), than that
induced by vehicle treatment, measured by EMSA.Values are reported as means 6 SEM; *P,0.05, **P,0.01, ***P,0.001 versus sham controls, and
{P,0.05,
{{{P,0.001 for wogonin-treated versus vehicle-treated TBI mice (n=7 mice/group).
doi:10.1371/journal.pone.0030294.g006
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suppressed MMP-9 expression in human aortic smooth muscle
cells [33,34]. It also ameliorated myocardial ischemia/reperfusion
injury, suppressed activation of NF-kB and p38 mitogen-activated
protein kinase and inhibited MCP-1 expression in vivo [35]. In the
CNS, wogonin attenuated LPS-induced production of NO and
pro-inflammatory cytokines in cultured microglia and astrocytes
[15,17,36] and suppressed microglial cell migration via inhibition
of NF-kB activity [13]. Additionally, it exhibited inhibitory effects
on inducible nitric oxide synthase (iNOS) protein expression and
MMP-9 enzyme activity in glioma cells [37]. These properties of
wogonin may contribute to its neuroprotective effects. Indeed,
inhibition of microglia by wogonin reduced cytotoxicity when cocultured with
PC12 cells [11]. In vivo experiments also showed that wogonin
treatment protected against brain damage by reducing the
production of inflammatory mediators, e.g., tumor necrosis factor
(TNF)-a and iNOS, preventing the death of hippocampal neurons
in cerebral ischemia [11], and inhibiting the activation of
microglia in excitotoxic brain injury [11].
We observed significant differences in brain water content and
EB extravasation between wogonin-treated and vehicle-treated
mice, providing evidence for the effects of wogonin on BBB
permeability and brain edema after TBI. Global cerebral edema,
or BBB dysfunction, has been reported as a major risk factor for
poor outcomes after TBI [38]. BBB dysfunction may potentially
allow circulating cells and many blood-borne substances into the
brain, thus augmenting cerebral inflammatory responses and
leading to further neuronal damage and edema formation.
Accumulating evidence shows that inflammation and activation
of MMPs play key roles in the disruption of the BBB and brain
edema formation after injury [28,38–40]. Furthermore, multiple
studies have shown that suppression of inflammation inhibited
BBB disruption and edema [5,41,42]. MMP-9 functions to
degrade the extracellular matrix, including major components of
the basal lamina and tight junctions as well as interendothelial
tight junction proteins, causing BBB disruption after TBI [28,38].
In addition, excessive accumulation of leukocytes causes the release
of cytotoxic enzymes, inflammatory mediators, and reactive oxygen
species, thereby potentially damaging the microvascular endothelium
and leading to BBB disruption and edema [31,38,39]. In the
current study, we showed that wogonin treatment decreased the
number of microglia, macrophages, and neutrophils recruited to
the injured areas of the brain, reduced NF-kB activation and
translocation to the nucleus, and interacted NF-kB binding
activity, expression of inflammatory mediators (IL-1b, IL-6,
MIP-2, and COX-2), and MMP-9 activity in the injured brain.
This reduction in inflammation was associated with the protection
of 2 tight junction proteins, ZO-1 and claudin-5, suggesting that
wogonin may act to protect endothelial tight junctions, thereby
keeping the BBB intact. Hence, the anti-edematous effect of
wogonin observed in our study is likely to be related to the
inhibition of inflammation. However, the beneficial effects of
Figure 7. Effects of 40 mg?kg
21 wogonin on TLR4 expresssion. (A) Representative immunoblots of toll-like receptor (TLR)-4 protein in the
ipsilateral hemisphere from untreated injured mice. Bar graphs of densitometry analysis of the protein bands showed increased TLR4 levels at 1, 3, 6
and 24 h post-injury (n=5 mice/time point). (B) Representative immunoblots showing TLR-4 protein in the ipsilateral hemisphere from a sham-
injured control, a wogonin-treated injured mouse, and a vehicle-treated injured mouse at day 1 post-TBI. Bar graphs of densitometry analysis of
protein bands showed a significant decrease in TLR4 protein levels in the ipsilateral hemispheres of wogonin-treated mice at day 1 post-TBI
compared with vehicle-treated mice. (C) Identification of TLR4- positive cells 1 day post-injury in the peri-contusion margin by immunofluorescence
labeling. TLR-4 immunoreactivity is shown in red, and immunolabeling of NeuN (a cell marker for neurons), anti-ionized calcium binding adaptor
molecule 1 (Iba1, a cell marker for microglia), or GFAP (a cell marker for astrocytes) is shown in green. Yellow labeling indicates co-localization. TLR4
was co-localized in neurons and astrocytes, and poor colocolization was observed in microglia. Sections were stained with DAPI (blue) to show all
nuclei. The scale bar is 50 mm. Values are reported as means 6 SEM; *P,0.05, **P,0.01, ***P,0.001 versus sham controls, and
{P,0.05 for wogonin-
treated versus vehicle-treated TBI mice (n=7 mice/group).
doi:10.1371/journal.pone.0030294.g007
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oxidant formation since wogonin exerts potent antioxidant effects
both in vitro [15,18] and in vivo [43,44]. Further investigations are
needed to clarify the mechanisms underlying the anti-edematous
effects of wogonin.
We found that a single post-injury injection of 40 mg?kg
21
wogonin protected against brain injury but did not induce renal or
liver toxicity in mice. The neuroprotective potential of wogonin
has been demonstrated in animal models of global and focal
ischemia as well as excitotoxic injury by systemic kainate injection
in rats. The effective doses ranged from 1 dose of 10 mg?kg
21
(10 mg?kg
21 given 10 min after induction of global ischemia) to 2
doses of 20 mg?kg
21 (20 mg?kg
21 given 30 min before and 4 h
after induction of focal ischemia) [16,17,33]. Nevertheless, all
previous studies only tested the efficacy of wogonin at fairly early
time points (1 to 7 days) after treatment. In contrast, our study
investigated structural parameters (infarct size), functional out-
comes, and physiological parameters (body weight, renal function,
and liver function) over a period of up to 1 month. Furthermore,
we found that post-injury wogonin treatment reduced cerebral
edema, BBB permeability, and apoptotic cell death, which are
major events that occur in the secondary injury phase of TBI.
Wogonin has a good safety profile, and it is already used in
humans in combination with other flavonoids extracted from S.
baicalensis Georgi for several different indications [9,45,46]. These
properties may facilitate clinical applications of wogonin to human
TBI patients. Further investigations will be required to establish
the optimal time window for treatment, route of administration,
and therapeutic efficacy for different injury magnitudes and
models.
In conclusion, our findings indicate that post-injury treatment
with wogonin leads to improved long-term functional and
histological outcomes and reduced brain edema in a clinically
relevant model of TBI. This improvement was associated with
attenuated expression of TLR4/NF-kB-pathway related media-
tors, including upstream factors (TLR4/NF-kB) and downstream
factors (IL-1b, IL-6, MIP-2, and COX-2 expression, and MMP-9
activity), suggesting that the neuroprotective effects of wogonin
following TBI may be mediated, in part, through modulation of
the TLR4/NF-kB signaling pathway. Wogonin treatment may
prove to be advantageous because chronic dosing is not required,
wogonin has low toxicity, and it can be easily administered in
emergency situations. Thus, wogonin could be a potential
therapeutic in the treatment of TBI.
Materials and Methods
Surgical procedures
All animal procedures were approved by the Animal Research
Committee at Cheng Hsin General Hospital (Animal permit
number CHGH-98-003), and all procedures conformed to the
Guide for the Care and Use of Laboratory Animals published by
the US National Institutes of Health (NIH Publication No. 85–23,
revised 1996). Animals were housed in groups in a temperature
(21–25uC)- and humidity (45–50%)-controlled room with a 12-h
light/dark cycle and ad libitum access to pellet chow and water. A
previously described CCI injury model was utilized [47]. Eight-
week-old male C57BL/6 mice (22–25 g body weight) were
intraperitoneally anesthetized with sodium pentobarbital
(65 mg?kg
21; Rhone Merieux, Harlow, UK) and placed in a
stereotaxic frame. A 5-mm craniotomy was performed over the left
parietal cortex, centered on the coronal suture and 3 mm lateral to
the sagittal suture. Considerable care was taken to avoid injury to
the underlying dura. Injury was induced using a pneumatic piston
with a rounded metal tip (2.5 mm diameter) which was vertically
angled (22.5u) so that the tip was positioned perpendicular, with
the brain surface at the center of the craniotomy. A velocity of
4m ?s
21 and a deformation depth of 2 mm below the dura were
used. The bone flap was immediately replaced and sealed, and the
scalp was sutured closed. Body temperature was monitored
throughout the surgery by using a rectal probe; temperature was
maintained at 37.060.5uC using a heated pad. Mice were placed
in a heated cage to maintain body temperature while recovering
from anesthesia.
Sham-operated mice received craniotomy as described before,
but without CCI; the impact tip was placed lightly on the dura
before sealing the wound. After the trauma or sham surgery,
animals were housed under the conditions mentioned above.
Experimental protocol and dose selection
All animals were randomized into 1 of 3 groups (sham injury,
CCI+vehicle, CCI+40 mg?kg
21 wogonin). Surgery/injury, behav-
ioral testing, and tissue analyses were all performed by different
individuals. Behavioral testing and tissue analyses were performed
by individuals blinded to the treatment group. Wogonin (Wako
Pure Chemical Industries, Osaka, Japan) dissolved in 30%
dimethyl sulfoxide (DMSO, 0.1 mL) or a corresponding volume
of vehicle (30% DMSO) was administered intraperitoneally
10 min following injury. Testing after injury was completed as
follows: 1) behavioral testing at days 1, 4, 7, 14, 21, and 28 (n=8
mice/group); 2) cresyl violet staining at days 1 and 28 (n=8 mice/
group); 3) histology, EB quantification, determination of brain
water content, western blot analysis, ELISA and EMSAs at day 1
(n=7 mice/group); and 4) real–time quantitative RT-PCR at 6 h
(n=7 mice/group). To determine the optimal dose of wogonin, a
pilot study was performed using 3 different doses (20, 40, and
50 mg?kg
21) administered 10 min after injury, and neurological
deficits were evaluated as main outcomes. The results showed a
significant effect of wogonin at 40 mg?kg
21, with no further
increase at 50 mg?kg
21. Therefore, on the basis of these data, a
dose of 40 mg?kg
21 was chosen for all subsequent experiments.
The temporal profile of TLR4 expression and NF-kB activation
was evaluated by western blot in another group of injured and
sham-injured mice. The purpose of this analysis was to determine
whether increased TLR4 expression and NF-kB activation
precede increased mRNA of pro-inflammatory mediators. Fol-
lowing CCI operation, western blot using whole-tissue or nuclear
extracts was performed at 1, 3, 6 and 24 h (n=5 for both TLR4
and NF-kB expression at each time point). Ten additional sham-
operated rats were used for the controls (n=5 for both TLR4 and
NF-kB western blot).
Neurological functional evaluation
Behavioral testing was performed before CCI and at 1, 4, 7, 14,
21, and 28 days after CCI. The battery of tests consisted of the
rotarod motor test, mNSS assessment, and beam walk test.
Animals were pre-trained for 3 days for both the rotarod and
beam walk tests.
Rotarod test. An accelerating rotarod was used to measure
motor function and balance in mice [24]. Each mouse was placed
on the rotarod cylinder, and the time that the animal remained on
the rotarod was measured. Speed was slowly increased from 4 rpm
to 20 rpm within 5 min. A trial would be ended if the animal fell
off the rungs or gripped the device and spun around for 2
consecutive revolutions without attempting to walk on the rungs.
One hour before CCI, the mean duration on the device was
recorded with 3 rotarod measurements as pre-injury baseline
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respective baseline values to reduce interanimal variability.
Modified neurological severity score. The mNSS is a
composite of motor, sensory, reflex, and balance tests [24]. One
point was scored for the inability to perform each test or for the
lack of a tested reflex; thus, the higher the score, the more severe
the injury. Neurological function was graded on a scale of 0–18
(normal score, 0; maximal deficit score, 18).
Beam walk test. The beam walk test was utilized to evaluate
fine motor coordination and function [24]. Mice escaped a bright
light and loud white noise by walking along an elevated (50 cm)
narrow wooden beam (0.8 cm6100 cm) to enter a darkened goal
box at the opposite end of the beam. The time required for the
mouse to reach the goal box (not to exceed 60 s) and hindlimb
performance as it traversed the beam (based on a 1 to 7 rating
scale) were recorded. A score of 7 was given when animals
traversed the beam with 2 or less foot slips; 6 was given when
animals traversed the beam with less than 50% foot slips; 5 was
given for more than 50% but less than 100% foot slips; 4 was given
for 100% foot slips; 3 was given for traversal with the affected limb
extended and not reaching the surface of the beam; 2 was given
when the animal was able to balance on the beam but not traverse
it; 1 was given when the animal could not balance on the beam.
Three trials were recorded 1 h before CCI (baseline) and each day
after CCI. The mean values of latency and score for each day were
computed.
Evaluation of metabolic characteristics
Following terminal anesthesia, venous blood was collected via
direct right atrial puncture. The obtained blood was centrifuged
(3500 rpm for 5 min), and the serum was stored at 220uC until
analysis. A chemistry analyzer (Synchron Clinical System LX20;
Beckman Coulter, Fullerton, CA) was used to measure serum BUN
and CRE to assess renal function, and AST and ALT to assess
liver function.
Tissue processing and histology
Following terminal anesthesia, mice were processed for
histology by transcardial perfusion with phosphate-buffered saline
(PBS) followed by 4% paraformaldehyde. All solutions were
maintained at pH 7.4 and 4uC. Brains were removed, post-fixed in
4% paraformaldehyde overnight, and then transferred to PBS
containing 30% sucrose and 0.1% sodium azide (Sigma-Aldrich,
St. Louis, MO) for cryoprotection. Coronal sections were cut in a
cryostat at 10 mm from the level of the olfactory bulbs to the visual
cortex and used for cresyl violet histology, FJB staining, TUNEL
staining, or immunohistochemistry.
Contusion volume and hemispheric enlargement analysis
Contusion volumes and hemispheric enlargement were quan-
tified using coronal sections stained with cresyl violet at 20 rostral-
caudal levels that were spaced 200 mm apart. Sections were
digitized and analyzed using a 1.56 objective and Image J
software (Image J, National Institutes of Health, Bethesda, MD).
The contusion area was calculated using all cresyl violet-stained
sections containing contused brain as previously described [24],
and the volume measurement was computed by summation of the
areas multiplied by the interslice distance (200 mm). Brain edema
was measured by determining the percentage of hemispheric
enlargement, which was calculated using the following formula:
[(ipsilateral hemisphere volume2contralateral hemisphere vol-
ume)/contralateral hemisphere volume]6100 [48]. Analysis was
conducted by two experimenters who were blinded to all animal
characteristics. Inter-rater reliability in contusion volumes and
hemispheric enlargement was well within 10%.
Evaluation of blood-brain barrier permeability
One day after TBI, BBB permeability was evaluated by
measuring EB extravasation. Briefly, EB dye (4 mL?kg
21 in 2%
saline) was administered via the tail vein and allowed to circulate
for 60 min. To wash out intravascular EB, the animals were then
perfused with saline through the left ventricle at a pressure of
110 mmHg until colorless fluid was obtained from the right
atrium. Brains were removed, and ipsilateral hemispheres were cut
into 4-mm-thick sections (2 mm from the frontal pole) and
weighed. For the extraction of EB from brain tissues, hemispheres
were placed in 1 mL of 60% (w/v) trichloroacetic acid and
homogenized by sonication. Homogenates were centrifuged at
4500 rpm for 15 min, and the supernatants were diluted with
ethanol (1:4). The absorbance of each supernatant for the EB dye
was measured at 620 nm using a spectrophotometer. EB
concentrations were calculated and expressed as mg?g
21 brain
tissue against a standard curve.
Brain water content
Brain water content represents brain edema, which forms as a
consequence of BBB breakdown and post-injury inflammation.
Mice were re-anesthetized and decapitated at day 1, a time point
associated with maximal edema formation following experimental
TBI [21]. Brain water content was measured by the tissue-drying
method in a 4-mm coronal tissue section of the ipsilateral
hemisphere, 2 mm from the frontal pole. The water content of a
sample was determined by measuring the difference between wet
weight (fresh tissue weight) and dry weight and expressed as a
fraction of the wet weight [42,48]. Brain samples were immedi-
ately weighed on an electric analytical balance to obtain the wet
weight and then dried at 100uC for 24 h to obtain the dry weight.
The water content of each sample (% water content) was
calculated using the following formula: (wet weight2dry
weight)/wet weight6100%.
FJB histochemistry
FJB is a polyanionic fluorescein derivative that binds with high
sensitivity and specificity to degenerating neurons, and staining
was done as previously described [49], with some modifications.
Briefly, sections were first incubated in a solution of 1% NaOH in
80% ethanol for 5 min and then rehydrated in graded ethanol (75,
50, and 25%; 5 min each) and distilled water. Sections were then
incubated in 0.06% KMnO4 for 10 min, rinsed in distilled water
for 2 min, and incubated in a 0.0004% solution of FJB (Chemicon,
Temecula, CA) for 30 min. Sections were observed and
photographed under a fluorescence microscope (Olympus BX-
51; Olympus, Tokyo, Japan) with blue (450–490 nm) excitation
light.
TUNEL staining
TUNEL assay was performed using a commercial kit that labels
DNA strand breaks with fluorescein isothiocyanate (FITC; In Situ
Cell Death Detection Kit, Roche Molecular Biochemicals,
Mannheim, Germany). Sections were pretreated with 20 mg/mL
proteinase-K in 10 mM Tris-HCl at 37uC for 15 min. The slices
were then washed in distilled water and PBS and incubated in
0.3% hydrogen peroxide solution. Each section was incubated
with 50 mL of TUNEL reaction mixture with terminal deoxynu-
cleotidyl transferase (TdT) for 60 min at 37uC under humidified
conditions. Sections were observed and photographed under a
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Negative controls were obtained by omitting the TdT enzyme.
Immunohistochemistry
All sections were dried, rehydrated in PBS, fixed in 4%
paraformaldehyde for 20 min, and rinsed in PBS. Sections were
then quenched in a solution of 10% methanol/10% hydrogen
peroxide in distilled water for 5 min before washing 3 times in
Tris-buffered saline (TBS; Sigma). Sections were blocked for
60 min in TBS containing 0.2% Triton X-100 (TXTBS; Sigma)
and 3% normal goat serum (NGS; Dako, Carpinteria, CA) and
then incubated overnight at 4uC with the respective primary
antibody (rabbit polyclonal anti-myeloperoxidase [MPO], a
neutrophil marker [Dako], or rabbit anti-Iba1, a microglia marker
[Wako]) in TXTBS containing 1% NGS. After 3 washes in TBS,
sections were incubated with a biotinylated secondary antibody
(biotinylated anti-rabbit IgG; Vector, Burlingame, VT) at a 1:200
dilution in TBS containing 1% NGS for 3 h, followed by 3 washes
in TBS. Detection of the primary antibody was facilitated by use of
a streptavidin-biotinylated horseradish peroxidase complex kit
(Dako), in which samples were incubated with diaminobenzidine
in TBS containing 1% NGS for 2 h, followed by 3 washes in TBS
and 2 washes in Tris non-saline (TNS). Sections were developed
with diaminobenzidine in TNS containing 0.03% hydrogen
peroxide, and excess stain was removed by washing in TNS 3
times. The specificity of the staining reaction was assessed by
several control procedures, including omission of the primary
antibody and substitution of the primary antibody with non-
immune rabbit serum.
In order to assess the cellular source of TLR4 after TBI, double
immunofluorescence labeling was performed by simultaneous
incubation of rabbit or goat polyclonal anti-TLR4 (1:100 dilution;
Santa Cruz Biotechnology, Santa Cruz, CA) with mouse anti-
neuronal nuclei antigen (1:100 dilution; NeuN, a neuronal marker;
Chemicon, Temecula, CA), rabbit polyclonal anti-Iba1 (1:100
dilution; a microglia marker; Wako), or rat monoclonal anti-glial
fibrillary acidic protein (GFAP, 1:400 dilution; an astrocyte
marker; Zymed Laboratories, South San Francisco, CA) overnight
at 4uC. Sections were then washed, incubated with Alexa Fluor
488 and Alexa Fluor 594 (1:400; Molecular Probes, Eugene, OR)
for 2 h, and examined under a fluorescence microscope (Olympus
BX-51; Olympus, Tokyo, Japan).
Quantification of FJB, TUNEL, MPO, and Iba-1 staining
FJB, TUNEL, MPO, and Iba-1 staining was quantified on
stained sections at the level of 0.74 mm from the bregma. Three
sections per animal were viewed and photographed under a
microscope. FJB-, TUNEL-, MPO-, and Iba1-positive cells were
counted by sampling an area of 128061024 mm
2 (for FJB, MPO,
and Iba1 staining) or 160061200 mm
2 (for TUNEL staining)
immediately adjacent to the cortical contusion margin in 3
randomly selected, non-overlapping fields using a magnification
of 6200. The total number of FJB-, MPO-, and Iba1-positive
cells was expressed as the mean number per field of view.
Quantification of TUNEL staining was expressed as the
percentage of nuclei that were stained by the TUNEL method
divided by the total number of DAPI-stained nuclei. Analysis was
conducted by 2 independent experimenters who were blinded to
all animal characteristics. Interrater reliability in cell counts was
within 10%.
Western blot analysis
Mice were re-anesthetized and decapitated 1 day after CCI or
sham operation for western blot analysis. A 4-mm coronal section
was taken from the injured area over the parietal cortex, and then
homogenized in ice-cold protein extraction reagents (T-PER
reagent; Pierce Biotechnology, Rockford, IL) containing a
complete mini protease inhibitor cocktail (Roche). Nuclear
extracts were prepared using a nuclear protein extraction reagent
kit (Marligen Biosciences Inc., Rockville, MD). Western blots were
performed as previously described [48]. Briefly, equal amounts of
protein were separated by sodium dodecyl sulfate-polyacrylamide
gel, transferred to Immobilon-P membranes (Millipore, Billerica,
MA), blocked using 5% milk in PBS containing 0.1% Tween-20,
and probed with primary antibodies at 4uC overnight. Afterwards,
the membranes were washed and incubated with horseradish
peroxidase-linked anti-rabbit or anti-mouse secondary antibodies
(1:1000 dilution; Santa Cruz Biotechnology) for 2 h. The relative
intensity of each protein signal was normalized to the correspond-
ing b-actin intensity and quantified by densitometry analysis using
Image J software. The following primary antibodies and dilutions
were used: 1) rabbit polyclonal anti-claudin-5 (1:1000 dilution;
Invitrogen, Camarillo, CA); 2) rabbit polyclonal anti-ZO-1 (1:200
dilution; Invitrogen); 3) rabbit polyclonal anti-COX-2 (1:1000
dilution; Cayman Chemical, Ann Arbor, MI); 4) rabbit polyclonal
anti-TLR4 (H-80; 1:1000 dilution; Santa Cruz Biotechnology); 5)
rabbit polycloncal anti NF-kB p65 (1:1000 dilution, Santa Cruz
Biotechnology); 6) mouse monoclonal anti-b-actin (1:5000 dilu-
tion; Sigma); 7) rabbit polycloncal anti-Lamin A/C (1:1000
dilution, Santa Cruz Biotechnology).
Enzyme-linked immunosorbent assay
Brains from injured or sham control animals were removed
without fixation after cervical dislocation 1 day following surgery.
A 4-mm coronal section was taken from the injured area over the
parietal cortex, snap-frozen in liquid nitrogen, and stored at
270uC until use. ELISAs were performed to detect IL-1b,I L - 6 ,
MIP-2, and MCP-1 in brain homogenates using commercially
available kits (R&D Systems, Minneapolis, MN). Tissue homog-
enates were diluted to correspond with the linear portion of the
respective standard curves as determined in preliminary studies.
All samples and standards were assayed in duplicate according to
the manufacturer’s instructions. Tissue cytokine and chemokine
concentrations were expressed as pg antigen per mg protein.
Gelatin zymography
One day after induction of TBI, mice were euthanized by
cervical dislocation and brains were removed without fixation.
Zymography was performed as previously described [48].
Briefly, equal amounts of protein (prepared in the same manner
as the samples for western blot analysis) were separated on a
10% Tris-glycine gel copolymerized with 0.1% gelatin as
substrate. After separation, the gel was washed twice in distilled
water (30 min each wash) and then, proteins within the gel were
renatured by incubation with 2.5% Triton-X-100 buffer for 1 h
at room temperature. After incubating with developing buffer
(0.05 M Tris-HCl pH 7.5, 0.2 M NaCl, 5 mM CaCl2,0 . 0 5 %
Brij-35, and 0.2 mM NaN3)a t3 7 uC for 24 h, the gel was stained
with 0.05% Coomassie R-250 dye (Sigma) for 30 min followed
by destaining. Gelatinolytic activity (MMP-9: ,97 kDa) was
indicated by the detection of clear bands at the appropriate
molecular weight.
Real-time quantitative RT-PCR
Six hours after injury or sham surgery, mice were euthanized by
cervical dislocation and brains from both injured and sham
animals were removed without fixation. A 4-mm coronal section
was taken from the injured area over the parietal cortex, snap-
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RNA was extracted from brain tissues using the RNeasy Mini Kit
(Qiagen, Valencia, CA) and subsequently subjected to reverse
transcription using SuperScript II RNase H reverse transcriptase
(Invitrogen). Real-time quantitative RT-PCR analysis was per-
formed on an ABI PRISM 7900 sequence detector (Applied
Biosystems, Foster City, CA). Primers and probes for IL-1b
(TaqMan Gene Expression Assay ID Mm00434228_ml), IL-6
(Mm00446190_ml), MIP-2 (Mm00436450_m1), MCP-1
(Mm00441242_m1), and COX-2 (Mm00478374_m1) were pur-
chased from Applied Biosystems. b-Actin (Rn00607939_s1) was
used as endogenous control. Thermal cycling was initiated with a
2-min incubation at 50uC, followed by a 10-min denaturation step
at 95uC and 40 cycles at 95uC for 15 s and 60uC for 1 min.
Relative quantities of the candidate genes and b-actin rRNA were
calculated using the previously described comparative threshold
cycle (Ct) method [25].
Electrophoretic mobility shift assay
Dissected cortices (prepared as in western blot analysis) were
extracted using a nuclear protein extraction reagent kit. EMSAs
were performed using a commercial kit according to the
manufacturer’s protocol (NF-kB EMSA kit; Panomics, Inc.,
Fremont, CA). Briefly, the double-stranded biotin-labeled NF-kB
oligonucleotide probe (59-AGTTGAGGGGACTTTCCCAGGC-
39) was incubated with the nuclear extracts in binding buffer and
poly[d(I-C)] for 30 min on ice. Samples were separated by
electrophoresis in 6% Tris-borate-EDTA (TBE) gels and trans-
ferred to nylon membranes. Oligonucleotides on the membranes
were fixed for 3 min using a UV crosslinker. After incubating with
blocking buffer at room temperature for 15 min, the membranes
were reacted with streptavidin-conjugated horseradish peroxidase
for another 15 min. After washing, the membranes were
incubated with detection buffer at room temperature for 5 min,
followed by incubation with chemiluminescent substrate solution
for another 5 min. Shifted bands corresponding to the protein/
DNA complexes were visualized relative to unbound double-
stranded DNA after exposure to a radiographic film. The
specificity of the binding reaction was evaluated by adding a 50-
fold excess of unlabeled probe to the protein/DNA reaction
mixture, which competes with the labeled DNA probe for binding
to the protein. For the supershift assay, a primary antibody
recognizing the p65 subunit of NF-kB (1:1000 dilution, Santa
Cruz) was incubated with the nuclear protein sample at 37uC for
1 h before performing the binding reaction. Optical densities of
the bands were quantified using Image J software.
Statistical analyses
Data are presented as the mean 6 standard error of the mean
(SEM). For comparisons among multiple groups, one-way or two-
way analysis of variance (ANOVA), followed by post-hoc
(Bonferroni) test, was used to determine significant differences.
Differences between 2 groups were tested using the Student’s t-test.
Statistical significance was set at P,0.05.
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